Safety review: Two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease
- 22 January 2007
- Vol. 25 (16) , 3080-3084
- https://doi.org/10.1016/j.vaccine.2007.01.022
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Persisting Immune Responses Indicating Long-Term Protection after Booster Dose with Meningococcal Group B Outer Membrane Vesicle VaccineClinical and Vaccine Immunology, 2006
- MeNZB™: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strainVaccine, 2005
- Immunogenicity of 2 Serogroup B Outer-Membrane Protein Meningococcal VaccinesJAMA, 1999
- New Zealand Epidemic of Meningococcal Disease Identified by a Strain with Phenotype B:4:P1.4The Journal of Infectious Diseases, 1998
- Adverse Outcomes of Bacterial Meningitis in School-Age SurvivorsPediatrics, 1995
- Sequelae one year after meningococcal diseaseActa Neurologica Scandinavica, 1994
- Cerebrovascular complications of bacterial meningitis in adultsNeurology, 1992
- Sequelae from bacterial meningitis and their relation to the clinical condition during acute illness, based on 667 questionnaire returns. Part II of a three part seriesJournal of Infection, 1983